ReviewRisk management and healthcare policy2022
An Overview of HPV Screening Tests to Improve Access to Cervical Cancer Screening Amongst Underserved Populations: From Development to Implementation.
Review in Risk management and healthcare policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Cervical cancer screening policy inequality worldwide: a systematic review of disparities in access and implementation.Journal of translational medicine · 2026Pooled it
- Liquid Biopsy Biomarkers for Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Development of a multiplex quantitative real-time PCR (qPCR) assay for simultaneous detection of Schistosoma haematobium and high-risk human papillomaviruses.PLoS neglected tropical diseases · 2026Article
- Risk-Stratified versus Cytology-Based Triage of Non-HPV 16/18-Positive for Detection of High-Grade Cervical Intraepithelial Neoplasia: Protocol of a Non- Inferiority Randomized Controlled Trial.Research square · 2026Article
- Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High-Risk Human Papillomavirus Genotyping in Cervical Samples.Journal of medical virology · 2026Article
- Cultural and religious influences on parental knowledge of HPV infection and female vaccination in Egypt: a national cross-sectional study.BMC public health · 2026Article
- Genotype-Specific HPV E6/E7 mRNA Triage Improves Risk Stratification and Reduces Referrals in DNA-Positive ASC-US/LSIL: A Real-World Cohort from Nordland, Norway.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Integrative molecular diagnostics for HPV-driven cervical carcinogenesis: a translational review of mechanisms and multimodal risk stratification.Frontiers in oncology · 2026Review
- Molecular, immunological and oncogenic mechanisms of cervical cancer mediated by HPV/HIV co-infection, clinical implication and management.Infectious agents and cancer · 2025Review
- Epidemiology of high-risk HPV in Uzbekistan among 44,000 women - genotypes, risk profiles and screening needs in Uzbekistan.BMC infectious diseases · 2025Article
- Advancements in Cervical Cancer Screening: Enhancing HPV Testing and Triage Strategies for Improved Risk Assessment.Biomedicines · 2025Review
- Molecular and serological prevalence of high-risk human papillomavirus among asymptomatic men in Georgia.IJID regions · 2025Article
- Culturally Competent Education and Human Papillomavirus Self-Sampling Achieves Healthy People 2030 Cervical Screening Target Among Low-Income Non-Hispanic Black and Hispanic Women.JCO global oncology · 2024Article
- Article
- Forecasting Head and Neck Cancer Trends in GCC Countries: Implications for Public Health Policy and Strategy.Risk management and healthcare policy · 2023Article
- Potential clinical utility of plasma D-dimer levels among women with cervical cancer in Lagos, Nigeria.Ecancermedicalscience · 2023Article
- The role of long noncoding RNAs in therapeutic resistance in cervical cancer.Frontiers in cell and developmental biology · 2022Review
- Delivering HPV results via telehealth: Patient needs and engagement following an at-home self-collection study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cervical cancer is the most common human papillomavirus (HPV)-related disease. Knowledge of the natural history and aetiology of cervical cancer offers unique opportunities for its prevention, and the development of HPV screening tests is one of the most effective strategies. The current HPV diagnostics detect HPV DNA or E6/E7 mRNA in cervical/vaginal samples using molecular-based technologies. HPV screening tests are more sensitive than cytology or visual inspection with acetic acid (VIA) as a primary screening method and are even more clinically valuable in triaging mild cytological abnormalities as a hybrid test. As technical and laboratory resources are grossly limited in marginalized or underserved settings which thus require that women travel long distances for screening and treatment. The practical implementation of an HPV-based screening programme may face many challenges and measures should be instituted to overcome these challenges without compromising disease detection. These measures may include a reduction in screening frequency using the WHO global strategy of offering HPV screening tests at 35 and 45 years of age, adoption of a high throughput testing technology, and improved access to vaginal HPV self-sampling screening tests to women in remote settings or those who are reluctant to undergo gynecologic examination. Another important strategy is the implementation of a "see-and-treat" approach using a point-of-care platform that requires limited skills of laboratory technicians. In addition, the development and large-scale incorporation of more specific HPV testing technologies that are much cheaper and easier to use in non-laboratory settings than the currently available options should be prioritized for underserved settings. At the same time, there is a need to develop and commence the implementation of an affordable and readily available intermediate or secondary test with optimal specificity for triaging or segregating clinically unimportant HPV infections that do not require colposcopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.